FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177458880> ?p ?o ?g. }

• W3177458880 endingPage "1103" @default.
• W3177458880 startingPage "1093" @default.
• W3177458880 abstract "Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-small-cell lung cancer patients receiving pembrolizumab. Patients & methods: We retrospectively identified 117 patients, divided into three prognostic groups according to LIPI score. For each patient, we evaluated 1-year overall survival (OS) and progression-free survival rate. C-statistic and survival receiver operating characteristic curves were used to study discrimination of LIPI. Results: After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year progression-free survival rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p < 0.001). The c-statistic and area under the curve of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively. Conclusions: Higher LIPI score is related to worse survival in advanced non-small-cell lung cancer patients treated with first-line pembrolizumab. However, based on c-statistic and area under the curve, LIPI does not represent a good prognostic survival model.Lay abstract In recent years, immunotherapy has become a milestone in the treatment of non-small-cell lung cancer, but clinicians need clinical and/or laboratory factors able to predict the benefit of immunotherapy. Therefore, we investigated the role of pretreatment lung immune prognostic index (LIPI) as biomarker in advanced non-small-cell lung cancer patients with high PD-L1 expression levels and receiving pembrolizumab as first line. We retrospectively identified 117 patients divided into three prognostic groups (good, intermediate and poor) according to LIPI score. We found that patients belonging to good prognostic group (LIPI score 0) lived longer and responded better than those of intermediate and poor prognostic groups (LIPI score 1 or 2), confirming the correlation between LIPI score and survival and response outcomes." @default.
• W3177458880 created "2021-07-05" @default.
• W3177458880 creator A5001969381 @default.
• W3177458880 creator A5022206145 @default.
• W3177458880 creator A5025797878 @default.
• W3177458880 creator A5027869659 @default.
• W3177458880 creator A5045548579 @default.
• W3177458880 creator A5051933262 @default.
• W3177458880 creator A5067404851 @default.
• W3177458880 creator A5073186349 @default.
• W3177458880 creator A5075400298 @default.
• W3177458880 creator A5081351883 @default.
• W3177458880 date "2021-09-01" @default.
• W3177458880 modified "2023-10-16" @default.
• W3177458880 title "Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab" @default.
• W3177458880 cites W2084139018 @default.
• W3177458880 cites W2115761859 @default.
• W3177458880 cites W2270932386 @default.
• W3177458880 cites W2397854274 @default.
• W3177458880 cites W2527905628 @default.
• W3177458880 cites W2762658547 @default.
• W3177458880 cites W2775559698 @default.
• W3177458880 cites W2784283849 @default.
• W3177458880 cites W2799913600 @default.
• W3177458880 cites W2914849482 @default.
• W3177458880 cites W2916339782 @default.
• W3177458880 cites W2916611783 @default.
• W3177458880 cites W2925446385 @default.
• W3177458880 cites W2940307933 @default.
• W3177458880 cites W2964098540 @default.
• W3177458880 cites W2973077527 @default.
• W3177458880 cites W2979117438 @default.
• W3177458880 cites W2987040069 @default.
• W3177458880 cites W2995043041 @default.
• W3177458880 cites W2995533566 @default.
• W3177458880 cites W3010387889 @default.
• W3177458880 cites W3016124046 @default.
• W3177458880 cites W3023081021 @default.
• W3177458880 cites W3136094932 @default.
• W3177458880 cites W52192959 @default.
• W3177458880 doi "https://doi.org/10.2217/imt-2021-0002" @default.
• W3177458880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34190578" @default.
• W3177458880 hasPublicationYear "2021" @default.
• W3177458880 type Work @default.
• W3177458880 sameAs 3177458880 @default.
• W3177458880 citedByCount "2" @default.
• W3177458880 countsByYear W31774588802022 @default.
• W3177458880 countsByYear W31774588802023 @default.
• W3177458880 crossrefType "journal-article" @default.
• W3177458880 hasAuthorship W3177458880A5001969381 @default.
• W3177458880 hasAuthorship W3177458880A5022206145 @default.
• W3177458880 hasAuthorship W3177458880A5025797878 @default.
• W3177458880 hasAuthorship W3177458880A5027869659 @default.
• W3177458880 hasAuthorship W3177458880A5045548579 @default.
• W3177458880 hasAuthorship W3177458880A5051933262 @default.
• W3177458880 hasAuthorship W3177458880A5067404851 @default.
• W3177458880 hasAuthorship W3177458880A5073186349 @default.
• W3177458880 hasAuthorship W3177458880A5075400298 @default.
• W3177458880 hasAuthorship W3177458880A5081351883 @default.
• W3177458880 hasConcept C121608353 @default.
• W3177458880 hasConcept C126322002 @default.
• W3177458880 hasConcept C143998085 @default.
• W3177458880 hasConcept C2776256026 @default.
• W3177458880 hasConcept C2776283816 @default.
• W3177458880 hasConcept C2777701055 @default.
• W3177458880 hasConcept C2780057760 @default.
• W3177458880 hasConcept C2781197716 @default.
• W3177458880 hasConcept C55493867 @default.
• W3177458880 hasConcept C58471807 @default.
• W3177458880 hasConcept C71924100 @default.
• W3177458880 hasConcept C86803240 @default.
• W3177458880 hasConceptScore W3177458880C121608353 @default.
• W3177458880 hasConceptScore W3177458880C126322002 @default.
• W3177458880 hasConceptScore W3177458880C143998085 @default.
• W3177458880 hasConceptScore W3177458880C2776256026 @default.
• W3177458880 hasConceptScore W3177458880C2776283816 @default.
• W3177458880 hasConceptScore W3177458880C2777701055 @default.
• W3177458880 hasConceptScore W3177458880C2780057760 @default.
• W3177458880 hasConceptScore W3177458880C2781197716 @default.
• W3177458880 hasConceptScore W3177458880C55493867 @default.
• W3177458880 hasConceptScore W3177458880C58471807 @default.
• W3177458880 hasConceptScore W3177458880C71924100 @default.
• W3177458880 hasConceptScore W3177458880C86803240 @default.
• W3177458880 hasIssue "13" @default.
• W3177458880 hasLocation W31774588801 @default.
• W3177458880 hasLocation W31774588802 @default.
• W3177458880 hasOpenAccess W3177458880 @default.
• W3177458880 hasPrimaryLocation W31774588801 @default.
• W3177458880 hasRelatedWork W2767114511 @default.
• W3177458880 hasRelatedWork W2786497694 @default.
• W3177458880 hasRelatedWork W2937519691 @default.
• W3177458880 hasRelatedWork W2969782175 @default.
• W3177458880 hasRelatedWork W2995652925 @default.
• W3177458880 hasRelatedWork W3161613553 @default.
• W3177458880 hasRelatedWork W3175277114 @default.
• W3177458880 hasRelatedWork W3215044659 @default.
• W3177458880 hasRelatedWork W4294938893 @default.
• W3177458880 hasRelatedWork W4322754005 @default.

• next